The Research and Development team at Lyell Immunopharma focuses on discovering and advancing innovative therapies for solid tumors by reprogramming T cells. This multidisciplinary team utilizes proprietary genetic and epigenetic reprogramming technologies to overcome barriers such as T cell exhaustion and loss of durable stemness. Team members collaborate to enhance T cell functionality through the development of T cell receptors (TCRs), tumor-infiltrating lymphocytes (TILs), and chimeric antigen receptors (CARs), aiming to create curative immunotherapies.
Alan Chiang
Head Of Biometrics
Bijan Boldajipour
Vice President Research
Bryan Selby
Senior Vice President, Clinica...
Gary Lee
Chief Scientific Officer
Lora Zhao
Scientist
Rachel Lynn
Senior Director
Shobha Potluri
Vice President Of Bioinformati...
Suman Kumar Vodnala
Vice President , Early T-cell ...
Tina Albertson
Chief Medical Officer & Head o...
Travis Beckett
Director, Flow Cytometry